{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T17:09:02Z","timestamp":1784740142177,"version":"3.55.0"},"reference-count":59,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,12,13]],"date-time":"2019-12-13T00:00:00Z","timestamp":1576195200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["IG 2015 - ID"],"award-info":[{"award-number":["IG 2015 - ID"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["17048"],"award-info":[{"award-number":["17048"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.jid.2019.08.454","type":"journal-article","created":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T18:04:53Z","timestamp":1572631493000},"page":"1045-1053.e6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Preclinical Evidence for Targeting PI3K\/mTOR Signaling with Dual-Inhibitors as a Therapeutic Strategy against Cutaneous T-Cell\u00a0Lymphoma"],"prefix":"10.1016","volume":"140","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3954-5481","authenticated-orcid":false,"given":"Antonella","family":"Bresin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3886-2485","authenticated-orcid":false,"given":"Cristina","family":"Cristofoletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9732-4700","authenticated-orcid":false,"given":"Elisabetta","family":"Caprini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4586-0920","authenticated-orcid":false,"given":"Maria","family":"Cantonetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9509-1405","authenticated-orcid":false,"given":"Alessandro","family":"Monopoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7718-9687","authenticated-orcid":false,"given":"Giandomenico","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8877-4611","authenticated-orcid":false,"given":"Maria Grazia","family":"Narducci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2019.08.454_bib1","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1158\/1078-0432.CCR-14-2422","article-title":"First-in-human pharmacokinetic and Pharmacodynamic Study of the dual m-TORC 1\/2 Inhibitor AZD2014","volume":"21","author":"Basu","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jid.2019.08.454_bib2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/978-1-4939-0733-5_4","article-title":"Introduction to digital PCR","volume":"1160","author":"Bizouarn","year":"2014","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.jid.2019.08.454_bib3","doi-asserted-by":"crossref","first-page":"4032","DOI":"10.1182\/blood-2014-11-610329","article-title":"The PI3K\/mTOR inhibitor PF-04691502 induces apoptosis and inhibits microenvironmental signaling in CLL and the E\u03bc-TCL1 mouse model","volume":"125","author":"Blunt","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jid.2019.08.454_bib4","doi-asserted-by":"crossref","first-page":"84659","DOI":"10.18632\/oncotarget.19109","article-title":"Novel combinations of PI3K-mTOR inhibitors with dacomitinib or chemotherapy in PTEN-deficient patient-derived tumor xenografts","volume":"8","author":"Brana","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jid.2019.08.454_bib5","doi-asserted-by":"crossref","first-page":"8438","DOI":"10.1158\/0008-5472.CAN-09-2367","article-title":"Identification of key regions and genes important in the pathogenesis of sezary syndrome by combining genomic and expression microarrays","volume":"69","author":"Caprini","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.jid.2019.08.454_bib6","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.4049\/jimmunol.1402610","article-title":"Bortezomib inhibits expression of TGF-beta1, IL-10, and CXCR4, resulting in decreased survival and migration of cutaneous T cell lymphoma cells","volume":"194","author":"Chang","year":"2015","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jid.2019.08.454_bib7","doi-asserted-by":"crossref","first-page":"135","DOI":"10.18632\/oncotarget.240","article-title":"Ras\/Raf\/MEK\/ERK and PI3K\/PTEN\/Akt\/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health","volume":"2","author":"Chappell","year":"2011","journal-title":"Oncotarget"},{"key":"10.1016\/j.jid.2019.08.454_bib8","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3892\/ijo.2015.3231","article-title":"PF-04691502, a dual PI3K\/mTOR inhibitor has potent pre-clinical activity by inducing apoptosis and G1 cell cycle arrest in aggressive B-cell non-Hodgkin lymphomas","volume":"48","author":"Chen","year":"2016","journal-title":"Int J Oncol"},{"key":"10.1016\/j.jid.2019.08.454_bib9","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1080\/15384101.2019.1617007","article-title":"Loss of \u03b2-arrestin-2 gene and possible functional consequences on Sezary Syndrome","volume":"18","author":"Cristofoletti","year":"2019","journal-title":"Cell Cycle"},{"key":"10.1016\/j.jid.2019.08.454_bib10","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1038\/s41375-018-0305-8","article-title":"Blood and skin-derived Sezary cells: differences in proliferation-index, activation of PI3K\/AKT\/mTORC1 pathway and its prognostic relevance","volume":"33","author":"Cristofoletti","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.jid.2019.08.454_bib11","doi-asserted-by":"crossref","first-page":"2","DOI":"10.21037\/cco.2018.11.02","article-title":"Sezary Syndrome, recent biomarkers and new drugs","volume":"8","author":"Cristofoletti","year":"2019","journal-title":"Chin Clin Oncol"},{"key":"10.1016\/j.jid.2019.08.454_bib12","doi-asserted-by":"crossref","first-page":"3511","DOI":"10.1182\/blood-2013-06-510578","article-title":"Comprehensive analysis of PTEN status in Sezary syndrome","volume":"122","author":"Cristofoletti","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jid.2019.08.454_bib13","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1038\/ng.3442","article-title":"The mutational landscape of cutaneous T cell lymphoma and Sezary syndrome","volume":"47","author":"da Silva Almeida","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.jid.2019.08.454_bib14","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ygyno.2016.04.019","article-title":"A\u00a0randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer","volume":"142","author":"Del Campo","year":"2016","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jid.2019.08.454_bib15","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1158\/1535-7163.MCT-13-0639","article-title":"Picking the point of inhibition: a comparative review of PI3K\/AKT\/mTOR pathway inhibitors","volume":"13","author":"Dienstmann","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jid.2019.08.454_bib16","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2174\/1389450114666140106100909","article-title":"Therapeutic targeting of cancers with loss of PTEN function","volume":"15","author":"Dillon","year":"2014","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.jid.2019.08.454_bib17","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/bjh.12945","article-title":"Time now to TORC the TORC? New developments in mTOR pathway inhibition in lymphoid malignancies","volume":"166","author":"Eyre","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jid.2019.08.454_bib18","doi-asserted-by":"crossref","first-page":"1726078","DOI":"10.1155\/2017\/1726078","article-title":"Resistance to mTORC1 inhibitors in cancer therapy: from kinase mutations to intratumoral heterogeneity of kinase activity","volume":"2017","author":"Faes","year":"2017","journal-title":"Oxid Med Cell Longev"},{"key":"10.1016\/j.jid.2019.08.454_bib19","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ccell.2017.01.014","article-title":"A\u00a0kinase inhibitor targeted to mTORC1 drives regression in glioblastoma","volume":"31","author":"Fan","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jid.2019.08.454_bib20","article-title":"Antitumor efficacy of the dual PI3K\/mTOR inhibitor PF-04691502 in a human xenograft tumor model derived from colorectal cancer stem cells harboring a PIK3CA mutation","volume":"8","author":"Fang","year":"2013","journal-title":"PLOS ONE"},{"key":"10.1016\/j.jid.2019.08.454_bib21","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1038\/leu.2015.103","article-title":"Versican upregulation in Sezary cells alters growth, motility and resistance to chemotherapy","volume":"29","author":"Fujii","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.jid.2019.08.454_bib22","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1007\/s10637-018-0578-9","article-title":"A\u00a0phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer","volume":"36","author":"Graham","year":"2018","journal-title":"Investig New Drugs"},{"key":"10.1016\/j.jid.2019.08.454_bib23","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1182\/blood-2011-04-346601","article-title":"Dual mTORC1\/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies","volume":"119","author":"Gupta","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jid.2019.08.454_bib24","doi-asserted-by":"crossref","first-page":"3808","DOI":"10.1158\/1078-0432.CCR-12-2716","article-title":"PI3K\/mTOR inhibitor PF-04691502 antitumor activity is enhanced with induction of wild-type TP53 in human xenograft and murine knockout models of head and neck cancer","volume":"19","author":"Herzog","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jid.2019.08.454_bib25","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1182\/blood-2017-08-802470","article-title":"Activity of the PI3K-\u03b4,\u03b3 inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma","volume":"131","author":"Horwitz","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jid.2019.08.454_bib26","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jdermsci.2013.12.003","article-title":"CCR7 expression correlates with subcutaneous involvement in mycosis fungoides skin lesions and promotes migration of mycosis fungoides cells (MyLa) through mTOR activation","volume":"74","author":"Hu","year":"2014","journal-title":"J\u00a0Dermatol Sci"},{"key":"10.1016\/j.jid.2019.08.454_bib27","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2014.269","article-title":"CXCR4 and CXCR7 transduce through mTOR in human renal cancer cells","volume":"5","author":"Ieran\u00f2","year":"2014","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.jid.2019.08.454_bib28","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1158\/0008-5472.CAN-08-3221","article-title":"Inhibition of constitutively activated nuclear factor-kappaB induces reactive oxygen species- and iron-dependent cell death in cutaneous T-cell lymphoma","volume":"69","author":"Kiessling","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.jid.2019.08.454_bib29","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1158\/1535-7163.MCT-11-0240","article-title":"In\u00a0vivo activity of combined PI3K\/mTOR and MEK inhibition in a Kras(G12D);Pten deletion mouse model of ovarian cancer","volume":"10","author":"Kinross","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jid.2019.08.454_bib30","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1038\/jid.2015.153","article-title":"Rapamycin suppresses tumor growth and alters the metabolic phenotype in T-cell lymphoma","volume":"135","author":"Kittipongdaja","year":"2015","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2019.08.454_bib31","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3389\/fonc.2017.00022","article-title":"Overview of the use of murine models in leukemia and lymphoma research","volume":"7","author":"Kohnken","year":"2017","journal-title":"Front Oncol"},{"key":"10.1016\/j.jid.2019.08.454_bib32","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s00281-016-0594-9","article-title":"Malignant inflammation in cutaneous T-cell lymphoma-a hostile takeover","volume":"39","author":"Krejsgaard","year":"2017","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.jid.2019.08.454_bib33","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/j.1600-0625.2010.01102.x","article-title":"Cutaneous T-cell lymphoma cells are sensitive to rapamycin","volume":"19","author":"Kremer","year":"2010","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jid.2019.08.454_bib34","doi-asserted-by":"crossref","first-page":"11686","DOI":"10.1038\/ncomms11686","article-title":"Stepwise phosphorylation of p65 promotes NF-\u03baB activation and NK cell responses during target cell recognition","volume":"7","author":"Kwon","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.jid.2019.08.454_bib35","doi-asserted-by":"crossref","first-page":"29187","DOI":"10.18632\/oncotarget.16304","article-title":"Combined inhibition of GLI and FLT3 signaling leads to effective anti-leukemic effects in human acute myeloid leukemia","volume":"8","author":"Latuske","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jid.2019.08.454_bib36","doi-asserted-by":"crossref","first-page":"437","DOI":"10.5114\/pdia.2015.48034","article-title":"Expression of CXCR4 and CXCL12 and their correlations to the cell proliferation and angiogenesis in mycosis fungoides","volume":"32","author":"Maj","year":"2015","journal-title":"Postepy Dermatol Alergol"},{"key":"10.1016\/j.jid.2019.08.454_bib37","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1182\/blood-2007-06-095182","article-title":"IL-2- and IL-15-induced activation of the rapamycin-sensitive mTORC1 pathway in malignant CD4+ T lymphocytes","volume":"111","author":"Marzec","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jid.2019.08.454_bib38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0024849","article-title":"Simultaneous inhibition of mTOR-containing complex 1 (mTORC1) and MNK induces apoptosis of cutaneous T-cell lymphoma (CTCL) cells","volume":"6","author":"Marzec","year":"2011","journal-title":"PLOS ONE"},{"key":"10.1016\/j.jid.2019.08.454_bib39","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/leu.2008.27","article-title":"Targeting survival cascades induced by activation of Ras\/Raf\/MEK\/ERK, PI3K\/PTEN\/Akt\/mTOR and Jak\/STAT pathways for effective leukemia therapy","volume":"22","author":"McCubrey","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.jid.2019.08.454_bib40","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.tibs.2011.03.006","article-title":"The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation","volume":"36","author":"Mendoza","year":"2011","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.jid.2019.08.454_bib41","doi-asserted-by":"crossref","first-page":"43013","DOI":"10.1038\/srep43013","article-title":"PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer","volume":"7","author":"Milella","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jid.2019.08.454_bib42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0024667","article-title":"Involvement of mTOR in CXCL12 mediated T cell signaling and migration","volume":"6","author":"Munk","year":"2011","journal-title":"PLOS ONE"},{"key":"10.1016\/j.jid.2019.08.454_bib43","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1182\/blood-2005-04-1492","article-title":"Skin homing of Sezary cells involves SDF-1-CXCR4 signaling and down-regulation of CD26\/dipeptidylpeptidase IV","volume":"107","author":"Narducci","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jid.2019.08.454_bib44","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1200\/JCO.2010.32.0630","volume":"29","author":"Olsen","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jid.2019.08.454_bib45","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1186\/s12885-017-3639-0","article-title":"Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors","volume":"17","author":"Philip","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jid.2019.08.454_bib46","doi-asserted-by":"crossref","first-page":"7137","DOI":"10.1158\/0008-5472.CAN-08-0602","article-title":"CXCL13 is highly produced by Sezary cells and enhances their migratory ability via a synergistic mechanism involving CCL19 and CCL21 chemokines","volume":"68","author":"Picchio","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.jid.2019.08.454_bib47","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/nature17963","article-title":"Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor","volume":"534","author":"Rodrik-Outmezguine","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.jid.2019.08.454_bib48","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/j.1365-2133.2004.06325.x","article-title":"Circulating clonal CLA(+) and CD4(+) T cells in Sezary syndrome express the skin-homing chemokine receptors CCR4 and CCR10 as well as the lymph node-homing chemokine receptor CCR7","volume":"152","author":"Sokolowska-Wojdylo","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2019.08.454_bib49","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/nrm3330","article-title":"The functions and regulation of the PTEN tumour suppressor","volume":"13","author":"Song","year":"2012","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.jid.2019.08.454_bib50","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejca.2017.02.027","article-title":"European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides\/Sezary syndrome - Update 2017","volume":"77","author":"Trautinger","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jid.2019.08.454_bib51","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s11523-017-0530-5","article-title":"A\u00a0multi-arm Phase I study of the PI3K\/mTOR inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK inhibitor PD-0325901 in advanced cancer","volume":"12","author":"Wainberg","year":"2017","journal-title":"Target Oncol"},{"key":"10.1016\/j.jid.2019.08.454_bib52","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/1523-1747.ep12616679","article-title":"Diagnostic value of T-cell receptor beta gene rearrangement analysis on peripheral blood lymphocytes of patients with erythroderma","volume":"99","author":"Whittaker","year":"1992","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2019.08.454_bib53","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO-EORTC\u00a0classification for cutaneous lymphomas","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jid.2019.08.454_bib54","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1182\/blood-2015-02-629543","article-title":"The mTORC1 inhibitor everolimus has antitumor activity in\u00a0vitro and produces tumor responses in patients with relapsed T-cell lymphoma","volume":"126","author":"Witzig","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jid.2019.08.454_bib55","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/leu.2010.226","article-title":"A\u00a0phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma","volume":"25","author":"Witzig","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.jid.2019.08.454_bib56","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1038\/jid.2009.45","article-title":"Cutaneous T-cell lymphoma: roles for chemokines and chemokine receptors","volume":"129","author":"Wu","year":"2009","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2019.08.454_bib57","first-page":"638","article-title":"mTOR signaling in tumorigenesis","volume":"1846","author":"Xu","year":"2014","journal-title":"Biochim Biophys Acta"},{"issue":"Database Issue","key":"10.1016\/j.jid.2019.08.454_bib58","first-page":"D955","article-title":"Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells","volume":"41","author":"Yang","year":"2013","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jid.2019.08.454_bib59","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1158\/1535-7163.MCT-11-0185","article-title":"PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity","volume":"10","author":"Yuan","year":"2011","journal-title":"Mol Cancer Ther"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X19333779?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X19333779?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T04:44:23Z","timestamp":1778647463000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X19333779"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":59,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S0022202X19333779"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2019.08.454","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical Evidence for Targeting PI3K\/mTOR Signaling with Dual-Inhibitors as a Therapeutic Strategy against Cutaneous T-Cell\u00a0Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2019.08.454","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}